Arcus Biosciences, Inc. (RCUS) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 188 institutional investors hold a position in Arcus Biosciences, Inc. (NYSE:RCUS).

• The collective stake of institutional investors in Arcus Biosciences moved to 94.7% in September 2025, a shift up from the 93.7% reported for June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 1.69%, with a year-over-year an increase of 1.08% in the count of filers.
• A review of institutional activity for Arcus Biosciences shows 88 of 188 filers increasing their positions, while 68 reduced their stake, and 32 remained unchanged.
• Collectively, institutional investors increased their stake in Arcus Biosciences to 100.74Mn shares as of September 2025, a change that is up by 1.67Mn shares quarter on quarter and up 47.52Mn shares year over year.
• GILEAD SCIENCES, INC.'s holding of 31.42Mn shares as of September 30, 2025 makes it the primary institutional investor in Arcus Biosciences, owning 29.53% of the stock.
• Among the most significant buyers of Arcus Biosciences during September 2025 were Siren, L.L.C. (1.30Mn), BANK OF AMERICA CORP /DE/ (863.16K), Fisher Asset Management, LLC (640.99K), Decheng Capital LLC (387.61K), BlackRock, Inc. (352.89K).
• Leading sellers of Arcus Biosciences stock in September 2025 included Point72 Asset Management, L.P. (1.63Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (291.00K), FMR LLC (277.27K), JANE STREET GROUP, LLC (244.36K), STATE STREET CORP (235.96K).
• The top 10 institutional holders of Arcus Biosciences for the quarter ending September 2025 included GILEAD SCIENCES, INC. (31.42Mn), BlackRock, Inc. (11.81Mn), VANGUARD GROUP INC (6.63Mn), Point72 Asset Management, L.P. (4.33Mn), Woodline Partners LP (3.77Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (3.69Mn), STATE STREET CORP (3.39Mn), Siren, L.L.C. (2.91Mn), FMR LLC (2.30Mn), GEODE CAPITAL MANAGEMENT, LLC (1.60Mn).